---
title: "Publications"
layout: page
---

We have categorized notable and foundational publications to give more information that relates to our work, the work of our colleagues, and the PRO research community. This list will be updated on a regular basis, as more publications are available.

<details open>
  <summary><b>Patient-reported outcomes (PROs):</b></summary>

  SPIRIT-PRO extension (PRO-specific protocol guidance):<br>  
  <a href="https://pubmed.ncbi.nlm.nih.gov/29411037/">Calvert et al, 2018</a> <br><br>
  
  SISAQOL recommendations (statistical standards for PRO data in randomized trials):<br>  
  [Coens et al, 2020](https://pubmed.ncbi.nlm.nih.gov/32007209/)<br><br>
  
  CONSORT-PRO extension:<br>  
  [Calvert et al, 2013](https://pubmed.ncbi.nlm.nih.gov/23443445/)<br><br>
  
  PRO-cision Medicine Toolkit (Medical Care edition focused on PROs implemented in clinical practice):<br>
  [Snyder et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985589/)<br>
    
  [Shi et al, 2016](https://pubmed.ncbi.nlm.nih.gov/30985590/)<br>
    
  [Cook et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985591/)<br>
    
  [Brown & Cano, 2019](https://pubmed.ncbi.nlm.nih.gov/30985592/)<br>
    
  [Jensen & Bjorner, 2019](https://pubmed.ncbi.nlm.nih.gov/30985593/)<br>
    
  [Oliver et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985594/)<br>
    
  [King et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985595/)<br>
    
  [Blackford et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985596/)<br>
    
  [Haverman et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985597/)<br>
    
  [Absolom et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985598/)<br>
    
  [Zahrieh et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985599/)<br>
    
  [Barbera & Moody, 2019](https://pubmed.ncbi.nlm.nih.gov/30985600/)<br>
    
  [Girgis et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985601/)<br>
    
  [Stover et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30985602/)<br><br>

</details>
--
<details open>
  <summary><b>PROMIS:</b></summary>

  PROMIS scales to PRO-CTCAE and single-item numeric rating scale items:<br>  
  [Lee et al, 2020](https://pubmed.ncbi.nlm.nih.gov/33305344/)<br><br>
  
  PROMIS reporting recommendations:<br> 
  [Hanmer et al, 2020](https://pubmed.ncbi.nlm.nih.gov/32215788/)<br><br>
  
</details>
--
<details open>
  <summary><b>PRO-CTCAE:</b></summary>

  Item generation:<br>  
  [Basch et al, 2014](https://pubmed.ncbi.nlm.nih.gov/25265940/)<br><br>
  
  Cognitive testing:<br>  
  [Hay et al, 2013](https://pubmed.ncbi.nlm.nih.gov/23868457/)<br><br>
  
  Validity, reliability, & responsiveness:<br>  
  [Dueck et al, 2015](https://pubmed.ncbi.nlm.nih.gov/26270597/)<br><br>
  
  Comparison of modes of administration (paper, web, & automated telephone):<br>  
  [Bennett et al, 2016](https://pubmed.ncbi.nlm.nih.gov/26892667/)<br><br> 
  
  Assessment of patient recall from 1 to 4 weeks:<br>  
  [Mendoza et al, 2017](https://pubmed.ncbi.nlm.nih.gov/28545337/)<br><br>
  
  Pediatric (and proxy) PRO-CTCAE:<br>  
  [Reeve et al, 2017](https://pubmed.ncbi.nlm.nih.gov/28062347/)<br><br>
  
  US FDA & NCI view on clinical review, IND safety reporting, & site inspections:<br>  
  [Kim et al, 2018](https://pubmed.ncbi.nlm.nih.gov/29237718/)<br><br>
  
  Strategy to select symptomatic AEs for administration:<br>  
  [Trask et al, 2018](https://pubmed.ncbi.nlm.nih.gov/30230365/)<br><br>
  
  What do “Mild”, “Moderate”, … mean to patients?:<br>  
  [Atkinson et al, 2018](https://pubmed.ncbi.nlm.nih.gov/29129739/)<br><br>
  
  Use of free text items:<br> 
  [Chung et al, 2019](https://pubmed.ncbi.nlm.nih.gov/30840079/)<br><br>
  
  Feasibility of PRO-CTCAE reporting:<br>  
  [Basch et al, 2017](https://pubmed.ncbi.nlm.nih.gov/28463161/)<br>
   
  [Basch et al, 2018](https://pubmed.ncbi.nlm.nih.gov/30204536/)<br><br>
  
  Composite scoring algorithm:<br>  
  [Basch et al, 2021](https://pubmed.ncbi.nlm.nih.gov/33258687/)<br><br>
  
  Example of PRO-CTCAE in a trial (PRO-CTCAE is reported in the supplemental appendix):<br>  
  [Gounder et al, 2018](https://pubmed.ncbi.nlm.nih.gov/30575484/)<br><br>
  
  PRO-CTCAE baseline adjustment method:<br>  
  [Dueck et al, 2020](https://pubmed.ncbi.nlm.nih.gov/31556911/)<br><br>

</details>
--
<details open>
  <summary><b>Adverse event (AE) analysis:</b></summary>
  
  Lancet Haematology Commission on modernizing approach to AEs:<br>  
  [Thanarajasingam et al, 2018](https://pubmed.ncbi.nlm.nih.gov/29907552/)<br><br>
  
  Update to Lancet Haematology Commission:<br>  
  [Thanarajasingam et al, 2022](https://pubmed.ncbi.nlm.nih.gov/35483398/)<br><br>
  
  Thanarajasingam ToxT references:<br>
  [Thanarajasingam et al, 2016](https://pubmed.ncbi.nlm.nih.gov/27083333/)<br>
    
  [Thanarajasingam et al, 2016](https://pubmed.ncbi.nlm.nih.gov/27396640/)<br>
    
  [Thanarajasingam et al, 2020](https://pubmed.ncbi.nlm.nih.gov/32470440/)<br>
    
  [Wong et al, 2021](https://pubmed.ncbi.nlm.nih.gov/32951293/)<br><br>

</details>
--
<details open>
  <summary><b>Rare diseases:</b></summary>
  
  [Boyd et al, 2016](https://pubmed.ncbi.nlm.nih.gov/26868354/)<br>
  
  [Blay et al, 2016](https://pubmed.ncbi.nlm.nih.gov/26868355/)<br>
  
  [Billingham et al, 2016](https://pubmed.ncbi.nlm.nih.gov/26868356/)<br><br>

</details>

--

<i>If you think a publication should be added, or are looking for more information, reach out to our team.</i>
